GestVision

GestVision, Inc. was founded with the mission to address the urgent need for early diagnosis of preeclampsia, a dangerous pregnancy-related condition characterized by high blood pressure and protein in the urine. The company's core vision is to improve maternal and fetal health outcomes globally through innovative diagnostic solutions. GestVision's primary product, the GestAssured test, is a point-of-care diagnostic tool designed to rapidly identify preeclampsia, making it accessible and practical for use in both developed and developing nations.

Notable figures associated with GestVision include researchers like Kara Rood and Irina A. Buhimschi, who have contributed significantly to the development of the Congo Red Dot (CRD) test, which underpins the GestAssured test. The company has received media coverage for its impactful work in maternal health. GestVision's key achievement lies in its potential to transform prenatal care by providing timely and accurate diagnosis of preeclampsia, thereby reducing the risk of severe complications and fatalities associated with the condition.